fig5
Figure 5. (A) Change in the proportion of myeloid dendritic cells (mDCs) expressing activation markers CD86 and HLA-DR. Expression level (MFI) of activation markers (CD86 and HLA-DR) on mDC after 4 weeks of supplementation with placebo or chRG-I. Data are baseline-corrected and presented as mean ± SEM (%) at week 4. Changes over time were analyzed using GEE with a Gaussian model, including baseline value, age, sex, BMI, and fiber intake as covariates. *: statistically significant difference compared to placebo over time (P < 0.05). chRG-I: RG-I derived from chicory root; HLA-D MFI: mean fluorescence intensity; SEM: standard error of the mean; GEE: Generalized Estimating Equations; BMI: body mass index.







